Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 6/2023

31-10-2023 | NSCLC | LUNG CANCER

Prognostic Impact of Cancer Inflammation Prognostic Index for Non-small Cell Lung Cancer

Authors: Nozomu Motono, Takaki Mizoguchi, Masahito Ishikawa, Shun Iwai, Yoshihito Iijima, Hidetaka Uramoto

Published in: Lung | Issue 6/2023

Login to get access

Abstract

Purpose

Cancer-inflammation prognostic index (CIPI) is calculated by multiplying the concentration of carcinoembryonic antigen by neutrophil-to-lymphocyte ratio. CIPI has been reported as a prognostic factor for colorectal cancer. Although carcinoembryonic antigen and neutrophil-to-lymphocyte ratio have been reported as prognostic factors for non-small cell lung cancer (NSCLC), it has not been investigated whether CIPI is a useful marker.

Methods

We analyzed the prognostic factors, including CIPI, in 700 NSCLC patients treated by pulmonary resection. We also analyzed a subgroup of 482 patients with pathological stage I NSCLC.

Result

CIPI > 14.59 (P < 0.01), maximum standardized uptake value (SUVmax) > 5.35 (P < 0.01), lymphatic invasion (P = 0.01), and pathological stage (P < 0.01) were significant factors for relapse-free survival (RFS) in multivariate analysis. SUVmax > 5.35 (P < 0.01) and pathological stage (P < 0.01) were revealed as significant factors for overall survival in the multivariate analysis. In the subanalysis, CIPI > 14.88 (P = 0.01) and SUVmax > 5.07 (P < 0.01) were significant factors for RFS of pathological stage I NSCLC in multivariate analysis.

Conclusion

CIPI was a significant factor for RFS in NSCLC patients treated surgically, even in those with pathological stage I disease. SUVmax was also a significant factor for RFS and overall survival in NSCLC patients treated surgically, and for RFS in patients with pathological stage I NSCLC.

Trial Registration

The Institutional Review Board of Kanazawa Medical University approved the protocol of this retrospective study (Approval Number: I392), and written informed consent was obtained from all patients.
Literature
1.
Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48CrossRefPubMed
2.
Zahorec R (2001) Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 102:5–14PubMed
3.
Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T (2011) Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 31:2995–2998PubMed
4.
Forget P, Machiels JP, Coulie PG, Berliere M, Poncelet AJ, Tombal B et al (2013) Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol 3:650–660CrossRef
5.
Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M (2015) Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer. World J Surg Oncol 13:291CrossRefPubMedPubMedCentral
6.
Motono N, Mizoguchi T, Ishikawa M, Iwai S, Iijima Y, Hidetaka U (2022) Prognostic value of neutrophil-to-lymphocyte ratio and prognostic nutrition index in patients with non-small cell lung cancer receiving pulmonary resection. World J Surg Res 5:1401
7.
Su YL, Tsai KL, Chiu TJ, Lin YM, Lee KC, Lu CC et al (2021) Development and validation of a novel serum prognostic marker for patients with metastatic colorectal cancer on regorafenib treatment. Cancers 13:5080CrossRefPubMedPubMedCentral
8.
You JF, Hsu YJ, Chern YJ, Cheng CC, Jong BK, Liao CK et al (2022) Preoperative cancer inflammation prognostic index as a superior predictor of short- and long-term outcomes in patients with stage I-III colorectal cancer after curative surgery. Cancers 14:6232CrossRefPubMedPubMedCentral
9.
Grunnet M, Sorensen JB (2012) Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 76:138–143CrossRefPubMed
10.
Brinkman GL, Coates EO (1963) The effect of bronchitis, smoking, and occupation on ventilation. Am Rev Respir Dis 87:684–693PubMed
11.
12.
Qiu C, Qu X, Shen X, Zheng C, Zhu L, Meng L et al (2015) Evaluation of prognostic nutritional index in patients undergoing radical surgery with nonsmall cell lung cancer. Nutr Cancer 67:741–747CrossRefPubMed
13.
Kim YS, Kim SJ, Kim TK, Kim IJ, Kim YD, Lee MK (2011) Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (Stage I and II) non-small cell lung cancer. Neoplasma 58:245–250CrossRefPubMed
14.
Nitadori J, Bograd AJ, Morales EA, Rizk NP, Dunphy MPS, Sima CS et al (2013) Preoperative consolidation-to-tumor ratio and SUVmax stratify the risk of recurrence in patients undergoing limited resection for lung adenocarcinoma ≤2cm. Ann Surg Oncol 20:4282–4288CrossRefPubMedPubMedCentral
15.
Motono N, Ueno M, Tanaka M, Machida Y, Usuda K, Sakuma T et al (2014) Differences in the prognostic significance of the SUVmax between patients with resected pulmonary adenocarcinoma and squamous cell carcinoma. Asian Pac J Cancer Prev 15:10171–10174CrossRefPubMed
16.
Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398:1344–1357CrossRefPubMed
17.
Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW et al (2021) Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. J Thorac Oncol 17:423–433CrossRefPubMed
18.
Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H et al (2004) A randomized trial of adjuvant chemotherapy with uracil-tagafur for adenocarcinoma for the lung. N Engl J Med 350:1713–1721CrossRefPubMed
19.
Tsutani Y, Imai K, Ito H, Miyata Y, Ikeda N, Nakayama H et al (2022) Adjuvant chemotherapy for high-risk pathologic stage I non-small cell lung cancer. Ann Thorac Surg 113:1608–2161CrossRefPubMed
20.
Rizzo A, Cantale O, Mogavero A, Garetto L, Racca M, Venesio T et al (2023) Assessing the role of colonic and other anatomical sites uptake by [18F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors. Thorac Cancer 14:2473–2483CrossRefPubMedPubMedCentral
21.
Cvetkovic L, Régis C, Richard C, Derosa L, Leblond A, Malo J et al (2021) Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging 48:1550–1559CrossRefPubMed
Metadata
Title
Prognostic Impact of Cancer Inflammation Prognostic Index for Non-small Cell Lung Cancer
Authors
Nozomu Motono
Takaki Mizoguchi
Masahito Ishikawa
Shun Iwai
Yoshihito Iijima
Hidetaka Uramoto
Publication date
31-10-2023
Publisher
Springer US
Keywords
NSCLC
NSCLC
Published in
Lung / Issue 6/2023
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-023-00649-z

Other articles of this Issue 6/2023

Lung 6/2023 Go to the issue

PULMONARY HYPERTENSION

A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension

COUGH

Recurrent Cough in the Elderly: A Forgotten Entity

LUNG TRANSPLANTATION

Predictive Value of CT Biomarkers in Lung Transplantation Survival: Preliminary Investigation in a Diverse, Underserved, Urban Population

SARCOIDOSIS

Methotrexate Polyglutamate Concentrations as a Possible Predictive Marker for Effectiveness of Methotrexate Therapy in Patients with Sarcoidosis: A Pilot Study

IDIOPATHIC PULMONARY FIBROSIS

MMP19 Variants in Familial and Sporadic Idiopathic Pulmonary Fibrosis

STATE OF THE ART REVIEW

Illuminating Airway Nerve Structure and Function in Chronic Cough
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits